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Abstract The molecular mechanism of action of MIF, a
cytokine that plays a critical role in the host immune and
inflammatory response, has not yet been identified. We recently
demonstrated that MIF is an enzyme that exhibits oxidoreduc-
tase activity by a cysteine thiol-mediated mechanism. Here we
further investigated this function by examining the reduction of
insulin disulfides by wild-type human MIF (wtMIF) using various
substrates, namely glutathione (GSH), dihydrolipoamide, L-
cysteine, L-mercaptoethanol and dithiothreitol. The activity of
wtMIF was compared to that of the relevant cysteine mutants of
MIF and to two carboxy-truncated mutants. Only GSH and
dihydrolipoamide were found to serve as reductants, whereas the
other substrates were not utilized by MIF. Reduction of insulin
disulfides by MIF was closely dependent on the presence of the
Cys57-Ala-Leu-Cys60 (CALC) motif-forming cysteines C57 and
C60, whereas C81 was not involved (activities : 51 þ 13%,
14 þ 5%, and 70 þ 12% of wtMIF, respectively, and 20 þ 3%
for the double mutant C57S/C60S). Confirming the notion that
the activity of MIF was dependent on the CALC motif in the
central region of the MIF sequence, the C-terminal deletion
mutants MIF(1^105) and MIF(1^110) were found to be fully
active. The favored use of GSH and dihydrolipoamide indicated
that MIF may be involved in the regulation of cellular redox
processes and was supported further by the finding that MIF
expression by the cell lines COS-1 and RAW 264.7 was
significantly induced upon treatment with the oxidant hydrogen
peroxide.
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1. Introduction
Our knowledge about the classical T cell cytokine macro-
phage migration inhibitory factor (MIF) [1,2] was vastly im-
proved by the recent ¢ndings that MIF is a pituitary hormone
and macrophage-derived cytokine playing a critical role dur-
ing the host in£ammatory and stress response [3^6]. In this
function, MIF was demonstrated to be a pro-in£ammatory
mediator of several in£ammatory diseases including Gram-
negative [3] and Gram-positive septic shock [7], and certain
immune-mediated and autoimmune diseases [8^10]. Of note,
MIF is the only cytokine to be induced by glucocorticoids and
then serves to function as an endogenous counter-regulator of
glucocorticoid action [5,11,12]. A possible mode of action of
MIF function is suggested by the surprising ¢nding that MIF
has enzymatic activity, showing both tautomerase [13,14] and
thiol-protein oxidoreductase activity [15,16]. Adding further
to an enzymatic role of MIF with likely physiological rele-
vance has been the current failure to identify a conventional
cytokine membrane receptor for MIF. A combined function
both as a cytokine and as an enzyme would not be unique to
MIF and has been shown previously for the protein mediators
thioredoxin/adult T cell leukemia-derived factor (ADF) [17] or
the cyclosporin A-binding factor cyclophilin [18].
Thiol-protein oxidoreductase activity has been investigated
widely for proteins of the thioredoxin superfamily [19^22] and
activity studies have been routinely performed using the insu-
lin reduction assay [23,24]. MIF was recently shown to cata-
lyze the reduction of insulin disul¢des [15]. Further studies are
needed to relate the identi¢ed enzymatic activity to the phys-
iological activities of MIF. An important step towards this
aim was taken in the present report. We studied the reduction
of insulin disul¢des by MIF using various physiologically oc-
curring reductants, namely dihydrolipoamide, L-cysteine, and
glutathione (GSH), as well as the non-natural substrates di-
thiothreitol (DTT) and L-mercaptoethanol. To con¢rm the
catalytic role of the putative disul¢de motif, Cys57-Ala-Leu-
Cys60 (CALC), of MIF for the insulin-reducing e¡ect, reduc-
tion of insulin disul¢des by wild-type human MIF (wtMIF)
was compared to the e¡ect brought about by the isosteric
cysteine mutants C57S, C60S, C57S/C60S, and C81S MIF.
Furthermore, the recently characterized carboxy-truncated
mutants MIF(1^105) and MIF(1^110) with deletions at a dis-
tance from the putative catalytic center as well as tri£uoro-
acetic acid (TFA)-modi¢ed MIF were examined. Lastly, in-
duction of MIF expression by the oxidant hydrogen peroxide
was analyzed by immunoblotting.
2. Materials and methods
2.1. Materials
Miscellaneous chemicals and enzymes were bought from Sigma-Al-
drich Chemicals (Deisenhofen, Germany) and were of the highest
grade commercially available. Escherichia coli thioredoxin (Trx) was
bought from Calbiochem (Heidelberg, Germany). Glutathione, L-cys-
teine, DTT, and L-mercaptoethanol were from Sigma-Aldrich Chem-
icals. Dihydrolipoamide was a kind gift from F. Vitzthum (University
of Stuttgart, Germany). Molecular biology reagents including oligo-
nucleotide primers for PCR cloning were acquired from Gibco-BRL
(Eggenstein, Germany) or New England Biolabs GmbH (Heidelberg,
Germany).
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2.2. Site-directed mutagenesis, cloning, bacterial expression, and
puri¢cation of wtMIF and the mutants
Human MIF was ampli¢ed originally from Jurkat H33HJ-JA1 T
cell DNA and cloned into the pET11b expression vector [6]. The
isosteric CysCSer mutants and the C-terminal deletion mutants of
human MIF were cloned from huMIF/pET11b by DNA ampli¢cation
as described [15,16].
Bacterial expression and puri¢cation of wtMIF and the mutants are
described in detail elsewhere [6,15,16] (Kleemann et al., submitted).
Brie£y, wtMIF, the CysCSer mutants (except for mutants C60S and
C57S/C60S), and the carboxy-truncated mutants were expressed and
puri¢ed essentially following the established protocol for wtMIF [6],
using isopropyl-1-thio-L-D-galactopyranoside-induced overexpression
of proteins in pET11b/E. coli BL21(DE3) and puri¢cation of recombi-
nant protein by the anion exchange and C8-SepPak reverse-phase
two-step chromatography procedure, and renaturation of acetoni-
trile-denatured protein by controlled dialysis. Puri¢cation of mutants
C60S and C57S/C60S was performed by a separate method involving
extraction of the protein from inclusion bodies, gel ¢ltration, and C8
reverse-phase chromatography (Kleemann et al., submitted).
2.3. Insulin reduction assay
MIF-catalyzed insulin reduction activity was examined following
the procedure of Chandler and Varandani [23] and Holmgren [24].
Brie£y, the insulin assay is based on the reduction of insulin and
subsequent insolubilization of the insulin L-chain. The time-dependent
increase in turbidity is then measured spectrophotometrically at
650 nm. Under standard conditions, the reaction was started by add-
ing 177.5 Wl of renatured MIF, TFA-modi¢ed MIF, or the mutants
(dissolved in 20 mM sodium phosphate bu¡er, pH 7.2) or a control
solution (containing bu¡er alone), and 22.5 Wl reductant to 700 Wl of
the ice-cold reaction mixture containing 1 mg/ml insulin, 100 mM
sodium phosphate bu¡er, pH 7.2, and 2 mM EDTA. The ¢nal con-
centration of wtMIF, TFA-modi¢ed MIF, and the MIF mutants was
1.8 WM. MIF-catalyzed insulin reduction was measured against the
control solution in the same experiment. For measuring TFA-modi-
¢ed MIF, 0.005% TFA was added to the control solution. Samples
were gently inverted every 10 min and turbidity followed for at least
2 h.
Mutant C57S/C60S was renatured by shock dilution from a 100%
(v/v) 2,2,2,2P,2P,2P-hexa£uoroisopropanol (HFIP) stock solution
(Kleemann et al., submitted). The ¢nal concentration of HFIP in
these samples was 0.2% (v/v). Control reactions for this mutant con-
taining wtMIF were renatured by an identical procedure and therefore
also contained 0.2% HFIP.
For analysis of the various substrates, an essentially identical pro-
tocol was applied. The reductants, except for dihydrolipoamide, were
dissolved in water and added to the assay at various concentrations.
Dihydrolipoamide was dissolved in acetone to prevent spontaneous
oxidation and 2.25 Wl of this solution were added to the assay to yield
a ¢nal concentration of 0.6 mM [24]. Prior experiments had demon-
strated that small volumes of up to 5 Wl acetone did not interfere with
the test.
The rate of precipitation of the insulin L-chain and the time of
onset were determined as described previously [15,24]. Data (rate of
precipitation) for the substrate screen using wtMIF represent at least
four independently performed experiments. Data representing the in-
sulin-reducing activity (rate of precipitation) of the mutants were from
at least ¢ve independent experiments and represent net curves with the
control spectra subtracted.
2.4. Cell culture and hydrogen peroxide induction
COS-1 cells were obtained from the German collection of micro-
organisms and cell lines (DSMZ, Braunschweig, Germany) and RAW
264.7 cells were a kind donation from R. Bucala (The Picower Insti-
tute for Medical Research, Manhasset, NY). COS-1 cells were main-
tained in EMEM medium (Gibco-BRL, Eggenstein, Germany) con-
taining 10% heat-inactivated fetal calf serum (FCS). RAW 264.7 cells
were cultured in RPMI 1640 medium containing 10% FCS. For in-
duction experiments, cells were transferred into 3.5-cm tissue culture
plates (2U106 cells/well), washed in the respective media containing
1% heat-inactivated FCS, and incubated in these media in a humidi-
¢ed atmosphere (37‡C and 5% CO2) for 1 h prior to H2O2 induction.
We ¢rst con¢rmed earlier ¢ndings that addition of 0.2 mM H2O2 did
not cause measurable cytotoxicity [25]. For induction, cells were
treated stepwise with 0.01 mM H2O2 for 3 h and then with 0.2 mM
H2O2 for an additional 2.5 h. Culture supernatants were collected,
concentrated 25-fold by membrane ¢ltration (10 kDa cut-o¡) (Cen-
tricon-10; Amicon GmbH, Witten, Germany), concentrated superna-
tants and cell pellets boiled in Laemmli electrophoresis bu¡er, and
proteins separated in 18% SDS polyacrylamide gels followed by West-
ern blotting as described previously [4]. Blotting membranes were
incubated ¢rst with polyclonal rabbit anti-mouse MIF serum and
then with alkaline phosphatase-conjugated goat anti-rabbit IgG anti-
body (Pierce-KMF Laborchemie, St. Augustin, Germany) (each di-
luted 1:1000). MIF was visualized with BCIP and NBT according to
the manufacturer’s protocol (Boehringer Mannheim, Mannheim, Ger-
many).
3. Results and discussion
We recently found that MIF functions to catalyze the re-
duction of insulin and 2-hydroxyethyl disul¢de (HED), thus
exhibiting thiol-protein oxidoreductase activity [15]. To fur-
ther investigate this novel function of MIF and to examine
the physiological relevance of this enzymatic activity, we
tested several reducing substrates in the insulin reduction as-
say. This substrate screen revealed that only GSH and dihy-
drolipoamide were utilized by MIF (Fig. 1). By contrast, no
signi¢cant reduction of insulin disul¢des was observed when
the reductants DTT, L-cysteine, and L-mercaptoethanol were
used. Analysis of the rate of precipitation of insulin at various
substrate concentrations showed that dihydrolipoamide was
used best by MIF. MIF activity in the presence of this reduc-
tant was more than 10 times higher than MIF-catalyzed re-
duction of insulin by glutathione at a comparable substrate
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Table 1
Catalysis of insulin reduction by wtMIF using various reductants
Substrate Concentration [mM] Rate of precipitation [A650/h]a Time of onset [min]
Dihydrolipoamide 0.6 0.395 26 (35)b
Glutathione 1.0 0.033 197 (315)
2.5 0.074 110 (185)
5.0 0.189 60 (105)
L-Cysteine 1.0 0 145 (135)
2.5 0 89 (89)
5.0 0 57 (57)
L-Mercaptoethanol 1.0 0 160 (160)
2.5 0.006 82 (82)
5.0 0.035 50 (53)
Dithiothreitol 1.0 0 32 (32)
5.0 0 13 (13)
Experiments were performed over a range of reductant concentrations and at a ¢nal MIF concentration of 1.8 WM.
aData represent net rates of precipitation with the substrate control values subtracted.
bNumbers in parentheses represent the time of onset values of the control substrate reactions without enzyme.
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concentration (Table 1). Reduction by dihydrolipoamide may
be even higher as the concentration of dihydrolipoamide used
was limited by the concentration of acetone which was used to
stably dissolve dihydrolipoamide and the dihydrolipoamide-
dependent reaction was even faster than that mediated by
GSH using 5 mM GSH (optimal concentration for GSH).
These ¢ndings were con¢rmed by the corresponding times
that were necessary for the MIF-catalyzed reaction to set in
(Table 1, time of onset). Reactions with dihydrolipoamide and
GSH (5 mM) precipitated after 26 and 60 min, respectively,
and were signi¢cantly faster than the substrate controls. By
contrast, the reactions with DTT, L-cysteine, and L-mercap-
toethanol precipitated considerably more slowly with values
close to those of the corresponding control reactions without
enzyme (Table 1).
In conclusion, speci¢c utilization of GSH and dihydrolipo-
amide by MIF suggested that these substrates might represent
physiological substrates of the investigated activity of MIF.
Oxidoreductase activity of MIF has been suggested to be
dependent on the presence of the CALC motif in the center of
the molecule [15]. Moreover, MIF mutants with the CALC-
derived cysteines exchanged have been found to lack the mac-
rophage-activating e¡ects of MIF [15]. CXXC-motif-contain-
ing enzymes play a broad role in the regulation of cellular
oxidation/reduction processes and the consensus stretch cys-
teines of these proteins are inter-converted between their di-
thiol and disul¢de forms during the enzymatic reaction. Ex-
amples are thioredoxin, glutaredoxin, thioredoxin reductase,
glutaredoxin reductase, or dihydrolipoamide dehydrogenase.
To con¢rm whether the observed enzymatic conversion by
MIF was mediated by the cysteines of the CXXC motif, i.e.
Cys57 and Cys60, and thus to further con¢rm the physiological
relevance of the enzymatic activity of MIF, various isosteric
mutants (Fig. 2) were subjected to the insulin reduction assay.
Both single mutants with Cys57 or Cys60 substituted and the
double mutant C57S/C60S were investigated. For control,
mutant C81S with the third cysteine residue of MIF that is
at distance from the CALC motif was used. In addition, two
carboxy-truncated mutants of MIF, MIF(1^105) and MIF(1^
110), were applied in the insulin reduction assay, as these
mutants had previously been shown to exhibit enzymatic ox-
idoreductase activity while lacking the cytokine-like activities
of MIF [16]. The C-terminal mutants have the C-terminal L-
strands L6 and L7 deleted which have been proposed to play a
role in trimer formation [16,26] of the MIF molecule, but
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Fig. 2. Primary and secondary structure of human MIF and location of mutations. Open arrows indicate L-strands and cylinders represent K-
helices. The sites of the deletions of mutant MIF(1^110) and MIF(1^105) are indicated by closed arrows and the sites of point mutations of
the cysteine mutants C57S, C60S, C57S/C60S and C81S are indicated by squares. Of note, numbering of the amino acids refers to the cDNA
sequence starting at Met1.
Fig. 1. MIF-catalyzed reduction of insulin by dihydrolipoamide
(DHL), glutathione (GSH), L-cysteine (CYS), L-mercaptoethanol
(LME), and dithiothreitol (DTT). Plot of the absorbance at 650 nm
against time. Recombinant wtMIF was tested at a protein concen-
tration of 1.8 WM with the respective reductants.
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deletions are at distance from the CALC motif by both se-
quence and three-dimensional means (Fig. 2).
Mutants were tested using the physiological substrate GSH
and the reactions compared to wtMIF (Fig. 3A,B). Insulin
precipitation curves showed that mutant C60S was essentially
inactive. This mutant only showed 14 þ 5% activity when com-
pared to wtMIF. The rate of insulin reduction by mutant
C57S was markedly faster than that by mutant C60S
(51 þ 13% of the activity of wtMIF), but no signi¢cant di¡er-
ence was observed when the times of onset were compared for
these two mutants. Mutant C81S exhibited signi¢cant activity
(70 þ 12% of the wild-type control). The observed reduction in
activity of mutant C81S compared to the wild type protein is
likely to represent a conformational e¡ect rather than to in-
dicate a direct contribution of Cys81 towards the enzymatic
reaction, as mutant C81S exhibits an overall activity spectrum
that is similar to wtMIF (Kleemann et al., in preparation).
Mutant C57S/C60S which required 0.2% HFIP to be present
in the reaction mixture was measured in a separate reaction.
Previous attempts to measure the enzymatic activity of this
mutant had failed due to the delicate solubility behavior of
this protein and the requirement to include HFIP in the sol-
vents [15]. Here, we found that 0.2% (v/v) HFIP did not
interfere with insulin reduction enabling us for the ¢rst time
to analyze the biological activity of mutant C57S/C60S. Con-
¢rming the above data obtained for the single mutants C57S
and C60S, mutant C57S/C60S was found to exhibit only
20 þ 3% of the activity of wtMIF (Fig. 3B).
Analyses of the time of onset were in overall agreement
with the measurements of the precipitation rate. Mutant
C60S precipitated last, with measurable turbidity detected 17
min after wtMIF and close to the substrate control. Mutants
C57S and C81S precipitated 6 min after the wild-type protein
(data not shown). The double mutant C57S/C60S was tested
in a separate reaction due to the special solvent requirements
and thus the time of onset was not comparable to the other
mutants. However, when compared to wtMIF tested under
identical solvent conditions, this mutant precipitated 28 min
slower than the wild-type protein and close to the substrate
control (not shown).
Both C-terminal mutants exhibited signi¢cant insulin-reduc-
ing activity when compared to wtMIF. We found that the
carboxy-truncated mutants exhibited an activity very similar
to wtMIF (Fig. 3A). The rates of precipitation of insulin
measured for these mutants were almost identical to that of
wtMIF (Fig. 3B) and the times of onset were closest to the
wild-type protein among all mutants (not shown). As ex-
pected, this demonstrated that the C-terminus of MIF was
not involved in the reduction of insulin disul¢des.
The obtained data, in particular the successful analysis of
mutant C57S/C60S requiring organic solvent to be present,
indicated to us that the insulin reduction assay could be a
valuable tool for structure activity investigations using a
broader range of MIF mutants and chemically modi¢ed
MIF derivatives. As a ¢rst step towards this aim, we applied
TFA-modi¢ed wtMIF to the assay. TFA is widely known to
react with basic amino acids such as Lys, Arg, and His to
form the corresponding TFA salts. TFA modi¢cation of
MIF was performed by incubating wtMIF in 0.005% (v/v)
TFA for 60 min. The resulting TFA-modi¢ed MIF showed
normal solubility and was subjected to the insulin reduction
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Fig. 3. Comparison of the various MIF mutants with wtMIF in the
MIF-catalyzed reduction of insulin by GSH. A: Plot of the absorb-
ance at 650 nm against time. Mutants were used at a protein con-
centration of 1.8 WM and compared to wtMIF at the same concen-
tration. Lactoglobulin and 20 mM sodium phosphate bu¡er, pH 7.2
(NaPP) containing the concentration of GSH, were used as negative
controls. For better comparison, curves represent net absorbances
with substrate control values subtracted. Data are representative of
three independent experiments. B: Relative activity of the mutants
and TFA-modi¢ed MIF in comparison to the insulin-reducing e¡ect
of wtMIF. The numbers indicate the relative activities with wtMIF
set at 100%. Data represent the mean þ S.E.M. of at least ¢ve as-
says.
Fig. 4. Induction of MIF protein by the oxidant H2O2. Western
blotting analysis of the intracellular (A) and secreted MIF levels (B)
following incubation of RAW 264.7 and COS-1 cells in the presence
(+) and absence (3) of H2O2. Recombinant human MIF (20 ng)
was electrophoresed and transferred as a reference.
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assay without further puri¢cation. TFA-modi¢ed MIF exhib-
ited 63 þ 8% of the activity of wtMIF (Fig. 3B) and catalysis
started 12 min later than that by wtMIF (not shown). Thus,
TFA-modi¢ed MIF that behaved normally otherwise was
only partially active. However, activity of this derivative was
much higher than the activities of the essentially inactive mu-
tants C60S and C57S/C60S. It is likely, therefore, that mod-
i¢cation of basic amino acids led to a number of small con-
formational changes resulting in the observed reduced activity
compared to wtMIF. Interestingly, modi¢cation of MIF by
fatty acids has also been reported to result in a reduced ac-
tivity of MIF [27] and such a modi¢cation is likely to also
involve basic amino acids.
In summary, these results con¢rmed the role of the CALC
sequence for the oxidoreductase activity of MIF. In particu-
lar, the importance of Cys60 which was found previously to be
essential for the HED-reducing and macrophage-activating
activities of MIF [15] was corroborated. Moreover, the ¢nding
that the cysteines of the CXXC motif were involved in con-
junction with the measured speci¢city for the substrates GSH
and dihydrolipoamide suggested that MIF may play a role in
the regulation of the cellular redox homeostasis. Glutathione
is a potent sulfhydryl reductant and plays a key role in main-
taining the cellular redox balance [28]. In this function, GSH
serves to protect cellular function against oxidative stress and
apoptosis [29]. Dihydrolipoamide has been shown to serve as
a therapeutic antioxidant with vitamin E- and GSH-like anti-
oxidant activity [30^33]. The redox potentials of the dihydro-
lipoamide/lipoamide and GSH/GSSG couple are 30.29 and
30.25 V, respectively [34]. By comparison, the redox potential
for the oxidized form of thioredoxin, i.e. the classical insulin-
reducing protein, is 30.26 V [24]. A redox potential for MIF
has not yet been determined, but the current data would sug-
gest that MIF also exhibits a reducing redox potential. One
putative MIF-regulated target within the cell is suggested by
the MIF-mediated antagonism of the immunosuppressive ef-
fects of glucocorticoids [5]. The glucocorticoid receptor which
has been thought to be regulated in its steroid-binding activity
by oxidation/reduction of a vicinally spaced pair of cysteine
residues [35] could be inactivated by a MIF-mediated redox
event in which GSH and/or dihydrolipoamide may be the
corresponding reductants.
Oxidants such as H2O2 have been shown to impose oxida-
tive stress onto cells leading to oxidation of the cellular GSH
pool [36]. To begin to investigate the role of MIF within the
complex cellular redox network, for example during oxidative
stress, induction of MIF by COS-1 and RAW 264.7 cells was
examined following treatment with H2O2. Treatment of both
cell lines with 0.2 mM H2O2 and subsequent Western blotting
analysis with a polyclonal anti-MIF antibody [4] resulted in a
marked secretion of MIF into the culture media, whereas no
increase in secretion was seen in the untreated control cells.
For COS-1 cells, which express only low levels of MIF protein
at baseline (A. Braun, unpublished observations), induction
by H2O2 also led to a signi¢cant increase in the intracellular
levels of MIF. Only a small H2O2-mediated increase in intra-
cellular MIF was observed in the RAW 264.7 macrophage
(Fig. 4). RAW 264.7 cells contain high baseline levels of intra-
cellular MIF that are released upon immune stimulation.
Although intracellular induction of MIF protein, i.e. de
novo synthesis, has not been studied in this cell type, immu-
nological induction of MIF mRNA levels has been shown to
parallel secretion of MIF protein. Thus, it would appear likely
that the H2O2-induced, intracellular levels of MIF were too
small to be detected, but that intracellular induction was
clearly indicated by the observed induction of MIF secretion.
Overall, these data were in accordance with a suggested role
for MIF in oxidative stress and cellular redox processes. By
contrast, the recent identi¢cation of MIF in the pancreas and
its colocalization to the insulin secretory granules of the pan-
creatic islet L-cell [37] is probably incidental and unlikely to
indicate a role for MIF in the regulation of insulin secretion
via the reduction of the insulin disul¢des.
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